KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBT: 2016-2024

Historic EBT for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$55.0 million.

  • Amneal Pharmaceuticals' EBT fell 133.87% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 155.75%. This contributed to the annual value of -$55.0 million for FY2024, which is 36.61% down from last year.
  • As of FY2024, Amneal Pharmaceuticals' EBT stood at -$55.0 million, which was down 36.61% from -$40.3 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' EBT ranged from a high of $31.4 million in FY2021 and a low of -$248.1 million during FY2022.
  • In the last 3 years, Amneal Pharmaceuticals' EBT had a median value of -$55.0 million in 2024 and averaged -$114.5 million.
  • In the last 5 years, Amneal Pharmaceuticals' EBT spiked by 187.66% in 2021 and then plummeted by 891.07% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' EBT (Yearly) stood at -$35.8 million in 2020, then skyrocketed by 187.66% to $31.4 million in 2021, then tumbled by 891.07% to -$248.1 million in 2022, then spiked by 83.77% to -$40.3 million in 2023, then crashed by 36.61% to -$55.0 million in 2024.